10-Q: TriSalus Reports Strong Revenue Growth Amidst Widened Net Loss

TriSalus Life Sciences, Inc. announced a 50.9% revenue increase for the nine months ended September 30, 2025, despite a significantly widened net loss primarily due to non-cash charges from preferred stock conversion.

Summary

• Revenue for the nine months ended September 30, 2025, increased by $10.8 million, or 50.9%, to $31.9 million compared to $21.2 million for the same period in 2024, driven by increased TriNav unit sales.
• Gross profit increased by $8.5 million, or 46.3%, to $26.7 million for the nine months ended September 30, 2025, but gross margin decreased to 83.7% from 86.4% due to lower manufacturing efficiency for newly launched products.
• Net loss attributable to common stockholders for the nine months ended September 30, 2025, significantly widened to $(59.9) million from $(22.3) million in 2024, primarily due to non-cash charges of $18.5 million for Series A Preferred Stock conversion inducement and $11.9 million for deemed dividends related to the conversion.
• Operating loss improved by $4.9 million, or 17.2%, to $(23.7) million for the nine months ended September 30, 2025, compared to $(28.6) million in 2024.
• Research and development expenses decreased by 15.8% to $12.4 million, mainly due to the close-out of nelitolimod clinical trials, partially offset by reclassified patent-related costs.
• Sales and marketing expenses increased by 10.1% to $20.7 million, driven by performance-related compensation tied to increased sales.
• General and administrative expenses increased by 29.9% to $17.3 million, primarily due to a $1.6 million non-cash stock-based compensation acceleration and reclassified patent-related expenses.
• Cash and cash equivalents increased to $22.7 million as of September 30, 2025, from $8.5 million at December 31, 2024, largely due to financing activities.
• The company raised $22.0 million gross proceeds from a Private Placement and drew $10.0 million from the First Delayed Draw Term Loan Commitment under the OrbiMed Credit Agreement during the nine months ended September 30, 2025.
• All Series A Convertible Preferred Stock was converted to Common Stock by July 31, 2025, eliminating this class of stock.
• Management identified material weaknesses in internal control over financial reporting and is implementing remediation plans.

Sentiment

Score: 4

Explanation: While revenue growth is strong and product development continues, the significant net loss, declining gross margin, and explicit 'going concern' warning indicate substantial financial challenges and risks. The material weaknesses in internal controls further add to the negative sentiment, despite successful capital raises and operational improvements in some areas.

Positives

• Revenue increased by 50.9% for the nine months ended September 30, 2025, to $31.9 million, indicating strong commercial performance of TriNav.
• Gross profit grew by 46.3% to $26.7 million for the nine months ended September 30, 2025.
• Operating loss improved by 17.2% to $(23.7) million for the nine months ended September 30, 2025, reflecting better operational efficiency.
• Cash and cash equivalents significantly increased to $22.7 million as of September 30, 2025, from $8.5 million at December 31, 2024, bolstered by successful financing rounds.
• Launched new PEDD devices: TriNav LV Infusion System, TriGuide Guiding Catheter (2024), and TriNav FLX (June 2025), expanding product portfolio and addressable market.
• Secured a second unique and permanent HCPCS code (C8004) for TriNav from CMS, effective April 1, 2025, providing clearer reimbursement for mapping procedures.
• Initiated the PROTECT registry study for Pressure Enabled Retrograde Occlusive Therapy with Embolization for Control of Thyroid Disease, potentially expanding the addressable market by approximately 50,000 procedures, representing an incremental $400 million market opportunity.
• Successfully drew $10.0 million from the First Delayed Draw Term Loan Commitment after achieving the required $30.0 million trailing 12-month Product Revenue Base.

Negatives

• Net loss attributable to common stockholders widened significantly to $(59.9) million for the nine months ended September 30, 2025, from $(22.3) million in 2024, primarily due to non-cash charges related to preferred stock conversion.
• Gross margin decreased to 83.7% from 86.4% for the nine months ended September 30, 2025, attributed to lower manufacturing efficiency for newly launched products.
• Interest expense increased by $2.1 million for the nine months ended September 30, 2025, due to additional debt from the OrbiMed Credit Agreement.
• The company reported liabilities greater than assets and has a history of operating losses, raising substantial doubt about its ability to continue as a going concern for at least one year.
• Material weaknesses in internal control over financial reporting were identified, indicating deficiencies in financial reporting processes.
• The change in fair value of SEPA, warrant, and revenue base redemption liabilities resulted in a larger loss of $(4.1) million for the nine months ended September 30, 2025, compared to $(1.5) million in 2024.

Risks

• Ability to raise future financing on satisfactory terms or at all, which is critical for funding future operations and long-term business plans.
• Ability to service indebtedness and access additional delayed draws under the OrbiMed Credit Agreement, which depends on achieving specific revenue milestones.
• Changes in applicable laws or regulations, particularly those affecting healthcare reimbursement and regulatory approvals.
• Ability to retain or recruit key officers, employees, or directors, which is vital for business continuity and strategic execution.
• Uncertainty regarding the successful commercialization of product candidates and the timing and results of clinical trials and regulatory approval applications for nelitolimod.
• Continued history of operating losses and expectations of significant expenses for the foreseeable future.
• Ability to maintain current TriNav pricing and gross margins, especially after the expiration of Transitional Pass-Through (TPT) payments and reliance on new HCPCS codes for reimbursement.
• The substantial cost and uncertain success of nelitolimod clinical trials, with no guarantee of favorable data or FDA approval.
• Ability to obtain and maintain intellectual property protection and avoid infringing on the rights of others.
• Challenges in managing growth effectively and maintaining the listing of securities on the Nasdaq Global Market.
• Potential negative outcomes from any legal proceedings that may be instituted against the company.
• Adverse conditions in the industry, global economy, or global supply chain, including financial and credit market fluctuations, international trade relations, pandemics, political turmoil, natural catastrophes, warfare, and terrorist attacks.
• Substantial doubt about the company's ability to continue as a going concern, which could lead to liquidation of assets at less than fair value.
• Identified material weaknesses in internal control over financial reporting, which could adversely affect the ability to accurately and timely report financial results.

Future Outlook

The company expects to continue incurring significant net losses due to ongoing investments in R&D, sales and marketing, and public company costs. Future operations and long-term strategy depend on raising additional capital through collaborations, strategic alliances, licensing, and further equity/debt issuances. Data from the PERIO-03 Phase I dose escalation study for nelitolimod in LA-PDAC is anticipated in late 2025, after which the company plans to seek a pharmaceutical partner for further clinical development, as it does not intend to proceed to Phase II trials alone due to excessive cost of capital. The company also aims to expand its addressable market with new PEDD devices and the PROTECT registry study for thyroid disease.

Management Comments

• We believe our current earnings, projections of future cash flows, financial condition, sources of liquidity and debt obligations raise substantial doubt about our ability to continue as a going concern for at least one year from the date of issuance of these condensed consolidated financial statements.
• Our ability to fund future operations and to continue the execution of our long-term business plan and strategy will require that we raise additional capital through a combination of collaborations, strategic alliances and licensing arrangements, and issuance of additional equity and/or debt.
• If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially, including a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring clinical trials and capital expenditures, and reducing other operating costs.
• The year-over-year decline in gross margin was primarily driven by lower manufacturing efficiency associated with newly launched products, which is a dynamic we expect to improve as production scales and processes mature.

Industry Context

TriSalus operates in the highly competitive oncology medical technology and immunotherapeutic space, focusing on solid tumors. The company's strategy of integrating innovative drug delivery technology (PEDD) with standard-of-care therapies and its investigational immunotherapeutic (nelitolimod) aims to address critical challenges like high intratumoral pressure and off-target delivery. The launch of new PEDD devices and securing additional HCPCS reimbursement codes are positive steps in a market that demands both technological advancement and clear pathways for adoption and payment. However, the high cost of clinical development, particularly for immunotherapeutics like nelitolimod, necessitates strategic partnerships, reflecting a common trend in the biotech industry where smaller firms seek larger pharmaceutical partners for late-stage development and commercialization.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential dilution from future equity raises, significant net losses, and the 'going concern' risk, but also benefit from revenue growth, new product launches, and potential for strategic partnerships.
• Employees: May be affected by potential workforce reductions, hiring freezes, or reductions in cash compensation if additional capital is not secured.
• Customers: Benefit from new and improved TriNav devices (TriNav LV, TriGuide, TriNav FLX) and clearer reimbursement pathways through new HCPCS codes.
• Creditors (OrbiMed): The OrbiMed Credit Agreement includes covenants and delayed draw commitments, with recent amendments providing waivers and adjusting liquidity requirements, impacting their risk exposure and potential returns.

Next Steps

• Seek a pharmaceutical partner for future clinical development of nelitolimod, particularly for Phase II trials, due to the excessive cost of capital.
• Anticipate data from the PERIO-03 Phase I dose escalation study in LA-PDAC in late 2025.
• Continue efforts to remediate identified material weaknesses in internal control over financial reporting.
• Evaluate the existing finance function experience and expertise to identify additional resource and application needs for remediation.
• Monitor the effectiveness of the remediation plan for internal controls and make appropriate changes.
• Potentially limit operations substantially, including hiring freezes, workforce reductions, cash compensation reductions, deferring clinical trials and capital expenditures, and reducing other operating costs if adequate capital resources are not available.

Key Dates

Recommendation

While TriSalus demonstrates strong revenue growth and a promising product pipeline with new device launches and expanded reimbursement codes, the significant net loss, declining gross margin, and explicit 'going concern' warning present substantial risks. The identified material weaknesses in internal controls further underscore operational challenges. The recent capital raises provide some liquidity, but the long-term financial stability remains uncertain. A 'hold' recommendation acknowledges the growth potential and recent financing efforts but advises caution due to the severe financial risks and operational control issues, suggesting investors monitor remediation efforts and future capital-raising success closely.

Keywords

TriSalus Life Sciences, TLSI, 10-Q, Quarterly Report, Oncology, Medical Technology, TriNav, PEDD, Nelitolimod, Clinical Trials, SEC Filing, Financial Results, Revenue Growth, Net Loss, Going Concern, HCPCS Code, OrbiMed Credit Agreement, Private Placement, Warrants, Preferred Stock Conversion, Internal Controls